Thomas Ferguson

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

Toni K. Choueiri, Piotr Tomczak, Se Hoon Park et al. · New England Journal of Medicine · 2021 · 746 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial

Laurence Albigès, Howard Gurney, Vagif Atduev et al. · The Lancet Oncology · 2023 · 149 citations

Medicine, Oncology, Pharmacotherapy +12

Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer

Sarah Barton, Lila Zabaglo, Roger A’Hern et al. · British Journal of Cancer · 2012 · 67 citations · Full text

Medicine, Oncology, Breast Oncology +12

Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).

Toni K. Choueiri, Piotr Tomczak, Se Hoon Park et al. · Journal of Clinical Oncology · 2024 · 35 citations

Medicine, Oncology, Pharmacotherapy +17